CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

$47.91 -2.52 (-5.00%)

Closing price 02/21/2025 04:00 PM Eastern

Extended Trading

$47.75 -0.16 (-0.33%)

As of 02/21/2025 07:59 PM Eastern

CRISPR Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
1

Hold
9

Buy
12

Based on 22 Wall Street analysts who have issued ratings for CRISPR Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 1 has given a sell rating, 9 have given a hold rating, and 12 have given a buy rating for CRSP.

Consensus Price Target

$74.40
55.29% Upside

According to the 22 analysts' twelve-month price targets for CRISPR Therapeutics, the average price target is $74.40. The highest price target for CRSP is $120.00, while the lowest price target for CRSP is $32.00. The average price target represents a forecasted upside of 55.29% from the current price of $47.91.

Get the Latest News and Ratings for CRSP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors.

CRSP Analyst Ratings Over Time

Type	Current Forecast 2/23/24 to 2/22/25	1 Month Ago 1/24/24 to 1/23/25	3 Months Ago 11/25/23 to 11/24/24	1 Year Ago 2/23/23 to 2/23/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)
Hold	9 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$74.40	$78.38	$74.94	$70.16
Forecasted Upside	55.29% Upside	77.20% Upside	56.51% Upside	-16.47% Downside
Consensus Rating	Moderate Buy	Hold	Hold	Hold

CRSP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRSP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CRISPR Therapeutics Stock vs. The Competition

Type	CRISPR Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	55.29% Upside	29,211.91% Upside	14.37% Upside
News Sentiment Rating	Neutral News See Recent CRSP News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/19/2025	Cantor Fitzgerald 4 of 5 stars	Eric Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
2/18/2025	Citigroup 3 of 5 stars	Yigal Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$89.00 ➝ $82.00	+56.82%
2/14/2025	Morgan Stanley 3 of 5 stars	Terence Flynn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underweight ➝ Underweight	$30.00 ➝ $32.00	-26.42%
2/14/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Liisa Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$60.00 ➝ $99.00	+127.64%
2/13/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$66.00 ➝ $57.00	+32.79%
2/13/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Benjamin Burnett Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$53.00 ➝ $49.00	+14.99%
2/13/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Silvan Tuerkcan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00	+101.83%
2/13/2025	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Geulah Livshits Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$94.00 ➝ $84.00	+94.00%
2/13/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00	+50.12%
2/12/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joon Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$100.00 ➝ $120.00	+183.07%
Get the Latest News and Ratings for CRSP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
2/12/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$53.00 ➝ $48.00	+12.29%
2/12/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$55.00 ➝ $56.00	+41.34%
2/12/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $84.00	+112.01%
2/12/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Van. Buren Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold	$35.00	-11.66%
1/7/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$98.00 ➝ $85.00	+100.24%
8/2/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.00	+64.08%
6/28/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Chattopadhyay Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
6/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $105.00	+71.65%
5/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$102.00 ➝ $95.00	+85.19%
5/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $65.00	+24.12%
5/9/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$46.00 ➝ $52.00	-2.42%
3/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$82.00 ➝ $99.00	+22.24%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$62.00 ➝ $63.00	+30.33%
5/30/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00	+15.99%
5/9/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$75.00	+38.63%
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$44.00	-1.03%
3/17/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+54.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:44 AM ET.

CRSP Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for CRISPR Therapeutics is $74.40, with a high forecast of $120.00 and a low forecast of $32.00.
: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There is currently 1 sell rating, 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRSP shares.
: According to analysts, CRISPR Therapeutics's stock has a predicted upside of 55.29% based on their 12-month stock forecasts.
: Over the previous 90 days, CRISPR Therapeutics's stock had 2 upgrades by analysts.
: CRISPR Therapeutics has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, Chardan Capital, Citigroup, Evercore ISI, HC Wainwright, JMP Securities, Morgan Stanley, Needham & Company LLC, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, and Truist Financial in the past 90 days.
: Analysts like CRISPR Therapeutics less than other "medical" companies. The consensus rating score for CRISPR Therapeutics is 2.50 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CRSP compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:CRSP) was last updated on 2/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Stock Forecast & Price Target